Lixisenatide
Adlyxin · Lyxumia · AVE0010
Once-daily short-acting GLP-1 RA (Adlyxin / Lyxumia), often with glargine as Soliqua. Post-meal glucose is the labeled job. This database has no vial fill.
Use-case scores
0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.
- Metabolic / weight7.5/10
Approved T2D, often with basal insulin (Soliqua). Ceiling 9 for approval; haircut because weight loss is modest and this site has no vial fill to recon.
Compound card
- Sequence
- Exendin-4 analog with C-terminal hexa-lysine
- Class
- Once-daily short-acting GLP-1 RA (Adlyxin / Lyxumia)
- Formula
- C215H347N61O65S
- Status
- Not FDA-approved · research use
How it works
Lixisenatide (Adlyxin® / Lyxumia®) is a once-daily GLP-1 receptor agonist derived from exendin-4 with 6 C-terminal lysine additions that extend its half-life vs native exenatide. It is approved for type 2 diabetes as an adjunct to basal insulin, making it particularly useful in combination with insulin glargine (as Soliqua® / Suliqua®). Its strongest action is on postprandial glucose - it slows gastric emptying aggressively, reducing meal-time glucose spikes more than other GLP-1 agents. Weight loss is modest (~2 kg vs semaglutide's 15-17%).
Source: PMID: 23404299 (GetGoal trials)
Research Use Cases
- ✓T2D with Basal Insulin: High
- ✓Postprandial Glucose Control: High
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Starting | 10 mcg | Once daily (SC, 1 hour before first meal) | 10 mcg for 14 days, then increase to 20 mcg maintenance. |
| Maintenance | 20 mcg | Once daily (SC) | Same time each day, always before the same meal. |
Administration
Timeline
Who it is for
T2D with Basal Insulin
HighFDA-approved. Combination with basal insulin (Soliqua) provides complementary coverage: basal handles fasting glucose, lixisenatide handles postprandial spikes.
Postprandial Glucose Control
HighStrongest gastric emptying delay of any GLP-1 - maximizes postprandial glucose reduction.
Safety & Considerations
FDA-approved (Adlyxin). Same class warnings as all GLP-1s: MTC/MEN 2 contraindication, pancreatitis risk. Hypoglycemia risk when combined with insulin or sulfonylureas - reduce insulin dose when starting.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- GetGoal / ELIXA describe branded lixisenatide, not a research cake.
- Short-acting gastric-emptying effect is not “stronger Wegovy.”
- No reconstitution row: commonVialSizes is empty in the calculator database.
Verdict
Lixisenatide is a labeled daily GLP-1 aimed at post-meal glucose, often paired with glargine as Soliqua. It is not a weekly obesity pen. This database has no vial size. Do not force it into the SubQ calculator.
Interactions & Contraindications
FDA-approved (Adlyxin). Same class warnings as all GLP-1s: MTC/MEN 2 contraindication, pancreatitis risk. Hypoglycemia risk when combined with insulin or sulfonylureas - reduce insulin dose when starting.
Frequently Asked Questions
What makes lixisenatide different from semaglutide?▼
Can lixisenatide be used with insulin?▼
References
- Riddle MC et al. “"Lixisenatide as add-on to basal insulin in T2D (GetGoal-L)".” Diabetes Care (2013). PMID: 23150280
📚 Related Articles
Looking for a trusted source? See our recommended suppliers
Independently tested · COA-verified · Save 10% with our exclusive code